# Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Source: https://onco.cc/trials/nct07148128/  
OnCo record `nct07148128` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of WEF-001 in pancreatic ductal adenocarcinoma, colorectal cancer and non-small-cell lung cancer, run by Auricula Biosciences Inc., now recruiting.

## Summary

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. is a phase 1/2 interventional study registered as NCT07148128 by Auricula Biosciences Inc., with 110 participants planned, started 2025-07-28 and due to reach its primary completion in 2028-01. Interventions recorded: WEF-001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07148128
- Phase: 1/2
- Setting: An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in Participants With Advanced KRAS- Mutant Solid Tumours.
- Sponsor: Auricula Biosciences Inc.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT07148128: https://clinicaltrials.gov/study/NCT07148128

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct07148128.json